Science
Mario Balsa on 4-1BB⁺ CD4 T Cells in Long-Term Melanoma Survivors
Mario Balsa/ LinkedIn

Mario Balsa on 4-1BB⁺ CD4 T Cells in Long-Term Melanoma Survivors

Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology, shared on X:

Long-term survivors after anti–PD-1 in advanced melanoma (n=58)! What about 4-1BB⁺ CD4 T cells?

Title: Long-term survivors of melanoma after anti–PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood

Authors: Karlijn de Joode , Hayri E Balcioglu , Mandy van Brakel , María T López-Cascales , Daan P Hurkmans , Edwin A Basak , Esther Oomen-de Hoop , Cor H Lamers , Joachim G Aerts , Ron H Mathijssen , Astrid A M van der Veldt , Reno Debets

Read The Full Article

Mario Balsa

Baseline CD4/CD8 T-cell subsets did not differ by survival

Long-term survivors showed an early increase in 4-1BB⁺ CD4 T cells during treatment

This was associated with increased LAG3⁺TIM3⁺ CD4 T cells and later reduced FOXP3⁺ CD4 T cells

On-treatment immune dynamics, rather than baseline, may better identify durable responders.”

Mario Balsa

4-1BB 4-1BB+ CD4 T Cells advanced melanoma Anti-PD-1 Astrid A.M. van der Veldt cancer cancer immunotherapy CD4 T cells CD8+ T cells Cor H Lamers Daan P Hurkmans Durable Responders Edwin A Basak Esther Oomen-de Hoop FOXP3 Hayri E Balcioglu Immune Checkpoint Inhibitors Immune Dynamics immunotherapy Joachim G Aerts Karlijn de Joode LAG3 long-term survivors Mandy van Brakel María T López-Cascales Mario Balsa Melanoma OncoDaily Oncology PD-1 Reno Debets Ron H Mathijssen skin cancer T cells TIM3